Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SB 9200 in Treatment Naive HCV Infected Adults

Trial Profile

A Phase 1a/1b Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SB 9200 in Treatment Naive HCV Infected Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Inarigivir soproxil (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 31 Mar 2016 According to a Spring Bank Pharmaceuticals media release, data from this trial will be presented at the International Liver Congress 2015, 51st annual meeting of the European Association for the Study of the Liver (EASL).
    • 16 Nov 2015 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top